225 related articles for article (PubMed ID: 29993147)
41. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
Ansell SM; Schilder RJ; Pieslor PC; Gordon LI; Emmanouilides C; Vo K; Czuczman MS; Witzig TE; Theuer C; Molina A
Clin Lymphoma; 2004 Dec; 5(3):202-4. PubMed ID: 15636698
[TBL] [Abstract][Full Text] [Related]
42. Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.
Illidge TM; Mayes S; Pettengell R; Bates AT; Bayne M; Radford JA; Ryder WD; Le Gouill S; Jardin F; Tipping J; Zivanovic M; Kraeber-Bodere F; Bardies M; Bodet-Milin C; Malek E; Huglo D; Morschhauser F
J Clin Oncol; 2014 Jan; 32(3):212-8. PubMed ID: 24297953
[TBL] [Abstract][Full Text] [Related]
43. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.
Lopci E; Santi I; Derenzini E; Fonti C; Savelli G; Bertagna F; Bellò M; Botto B; Huglo D; Morschhauser F; Zinzani P; Fanti S
Ann Oncol; 2010 Sep; 21(9):1877-1883. PubMed ID: 20147744
[TBL] [Abstract][Full Text] [Related]
44. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
Ulaner GA; Colletti PM; Conti PS
Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
[TBL] [Abstract][Full Text] [Related]
45. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
[TBL] [Abstract][Full Text] [Related]
46. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
[TBL] [Abstract][Full Text] [Related]
47. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.
Goff L; Summers K; Iqbal S; Kuhlmann J; Kunz M; Louton T; Hagenbeek A; Morschhauser F; Putz B; Lister A; Rohatiner A
J Clin Oncol; 2009 Dec; 27(36):6094-100. PubMed ID: 19858392
[TBL] [Abstract][Full Text] [Related]
48. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Leahy MF; Turner JH
Blood; 2011 Jan; 117(1):45-52. PubMed ID: 20864582
[TBL] [Abstract][Full Text] [Related]
49. Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).
Lansigan F; Costa CA; Zaki BI; Yen SP; Winer ES; Ryan H; Findley D; Metzler SR; Shaw L; Toaso B; MacKenzie TA; Chen Y; Beaven AW
Clin Cancer Res; 2019 Oct; 25(20):6073-6079. PubMed ID: 31243122
[TBL] [Abstract][Full Text] [Related]
50. Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.
Alhaj Moustafa M; Borah BJ; Moriarty JP; Dholakia R; Jiang L; Li K; Witzig TE; Hoppe BS; Peterson J; Cerhan JR; Tun HW
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):259-265. PubMed ID: 36775698
[TBL] [Abstract][Full Text] [Related]
51. The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma.
Laoruangroj C; Atherton PJ; Wiseman GA; Ansell S; Feldman AL; Schumacher P; Witzig TE
Leuk Lymphoma; 2024 Mar; 65(3):333-338. PubMed ID: 38189774
[TBL] [Abstract][Full Text] [Related]
52. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
53. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M
Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293
[TBL] [Abstract][Full Text] [Related]
54. 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Rieger K; De Filippi R; Lindén O; Viardot A; Hess G; Lerch K; Neumeister P; Stroux A; Peuker CA; Pezzutto A; Pinto A; Keller U; Scholz CW
Ann Hematol; 2022 Apr; 101(4):781-788. PubMed ID: 35150296
[TBL] [Abstract][Full Text] [Related]
55. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
Cheson BD
BioDrugs; 2005; 19(5):309-22. PubMed ID: 16207072
[TBL] [Abstract][Full Text] [Related]
56. Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan.
Andrade-Campos MM; Liévano P; Espinosa-Lara N; Soro-Alcubierre G; Grasa-Ulrich JM; López-Gómez L; Baringo T; Giraldo P
Eur J Haematol; 2016 Dec; 97(6):576-582. PubMed ID: 27157440
[TBL] [Abstract][Full Text] [Related]
57. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
[TBL] [Abstract][Full Text] [Related]
58. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
Zinzani PL; Tani M; Pulsoni A; De Renzo A; Stefoni V; Broccoli A; Montini GC; Fina M; Pellegrini C; Gandolfi L; Cavalieri E; Torelli F; Scopinaro F; Argnani L; Quirini F; Derenzini E; Rossi M; Pileri S; Fanti S; Baccarani M
Ann Oncol; 2012 Feb; 23(2):415-20. PubMed ID: 21536660
[TBL] [Abstract][Full Text] [Related]
59. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Johnston PB; Bondly C; Micallef IN
Expert Rev Anticancer Ther; 2006 Jun; 6(6):861-9. PubMed ID: 16761929
[TBL] [Abstract][Full Text] [Related]
60. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant.
Arnason JE; Luptakova K; Rosenblatt J; Tzachanis D; Avigan D; Zwicker JI; Levine J; Kim M; Parker JA; Grant B; Joyce RM
Acta Haematol; 2015; 133(4):347-53. PubMed ID: 25677780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
